Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells

Molecular Medicine Reports

Volumn 2, Issue 1, 2009, Pages 121-127

  Ge, Yin Lin ^a   Zhang, Jin Yu ^a   Zhang, Xiao ^a   Hou, Lin ^a   Li, Quan ^a   Xue, Mei Lan ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Breast cancer; Kinase insert domain containing receptor; RNA interference; Small interfering RNA; Vascular endothelial growth factor receptor 2

Indexed keywords

CYCLIN DEPENDENT KINASE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR GROWTH;

EID: 69249155266     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000072     Document Type: Article

References (24)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
2. Shinkaruk S, Bayle M, Lain G and Déléris G: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy, Curr Med Chem Anticancer Agents 3: 95-117, 2003.
3. Yuriko K and Masaru K: Comparative integromics on VEGF family members. Int J Oncol 28: 1585-1589, 2006.
4. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
5. Masood R, Cai J, Zheng T, Smith DL, Hinton DR and Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98: 1904-1913, 2001.
6. De Jong JS, van Diest PJ, van der Valk P and Baak JP: Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 184: 53-57, 1998. (Pubitemid 28086153)
7. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S and Leite V: Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 153: 701-709, 2005. (Pubitemid 41672417)
8. Lacal PM, Ruddini F, Pagani E and D'Atri S: An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 27: 1625-1632, 2005.
9. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S and Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-transretinoic acid. Oncogene 24: 8025-8037, 2005. (Pubitemid 41746746)
10. Wheeler YY, Kute TE, Willingham MC, Chen SY and Sane DC: Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J 17: 1733-1735, 2003.
11. Bange J, Zwick E and Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med 7: 548-552, 2001. (Pubitemid 32448320)
12. Ganz PA: The role of hormones in breast carcinogenesis: issues of relevance to female childhood cancer survivors. Med Pediatr Oncol 36: 514-518, 2001.
13. Försti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, Grzybowska E, Pamula J, Pekala W, Hallmans G, Lenner P and Hemminki K: Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat 101: 83-93, 2007. (Pubitemid 47555326)
14. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE and Landberg G: Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82: 147-154, 2003. (Pubitemid 37521970)
15. Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013-2016, 1996. (Pubitemid 26119899)
16. An LF and Dong Z: RNA interference - new tool for the tumor research. Chin J Oncol 27: 385-388, 2005.
17. De Souza Nascimento P, Alves G and Feidler W: Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncol Rep 16: 423-428, 2006.
18. Dorsett Y and Tuschl T: siRNAs applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3: 318-329, 2004. (Pubitemid 38499759)
19. Dykxhoorn DM, Novina CD and Sharp PA: Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4: 457-467 2003.
20. Kasukabe T, Okabe-Kado J, Kato N, Sassa T and Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation- inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7: R1097-R1110, 2005.
21. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA and Sullenger BA: In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771, 2004.
22. Hamada M, Ohtsuka T, Kawaida R, Koizumi M, Morita K, Furukawa H, Imanishi T, Miyagishi M and Taira K: Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev 12: 301-309, 2002. (Pubitemid 35375495)
23. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV and Woodle MC: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149, 2004.
24. Maria GC, Nicoletta F, Mariateresa P, Lucia C, Roberta P, Ornella B and Giuseppe B: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90: 1383-1389, 2005.